(PXF) Invesco FTSE RAFI Developed - Ratings and Ratios
Exchange: NYSE ARCA • Country: USA • Currency: USD • Type: Etf • ISIN: US46138E7435
PXF: Foreign, Large-Cap, Value, Stocks
The Invesco FTSE RAFI Developed Markets ex-U.S. ETF is an investment vehicle that tracks the performance of the largest non-U.S. developed market companies, focusing on fundamental measures of company size rather than market capitalization. This approach aims to provide a more balanced representation of the underlying companies economic footprint.
The funds underlying index is constructed using four key metrics: book value plus intangibles, adjusted cash flow, adjusted sales, and dividend plus buybacks. By considering these factors, the index provider seeks to create a more comprehensive picture of a companys size and financial health, potentially leading to a more stable and value-oriented investment portfolio.
Analyzing the funds technical data, we observe a bullish trend, as the last price is above the 20-day and 50-day simple moving averages (SMA20 and SMA50). The Average True Range (ATR) indicates relatively low volatility, suggesting a stable price environment. Given the current price is at its 52-week high, we can anticipate potential resistance at this level. However, if the price consolidates above the SMA20, it may attract further buying interest.
By combining the technical analysis with fundamental data, we note that the funds Assets Under Management (AUM) stand at approximately $2.02 billion. This size provides sufficient liquidity and scale for the fund to operate efficiently. Considering the current market environment and the funds characteristics, we forecast that PXF may continue to perform well in the near term, potentially targeting the $60 level, driven by the ongoing demand for large-cap, non-U.S. developed market companies with strong fundamental profiles.
Investors should be aware that the funds performance is closely tied to the overall health of the global economy and the relative performance of non-U.S. developed markets versus the U.S. market. As such, any significant shifts in global economic trends or currency fluctuations could impact the funds performance.
Additional Sources for PXF ETF
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle
PXF ETF Overview
Market Cap in USD | 2,023m |
Category | Foreign Large Value |
TER | 0.45% |
IPO / Inception | 2007-06-25 |
PXF ETF Ratings
Growth Rating | 70.7 |
Fundamental | - |
Dividend Rating | 63.1 |
Rel. Strength | 8.2 |
Analysts | - |
Fair Price Momentum | 58.10 USD |
Fair Price DCF | - |
PXF Dividends
Dividend Yield 12m | 3.32% |
Yield on Cost 5y | 5.89% |
Annual Growth 5y | 13.18% |
Payout Consistency | 87.1% |
Payout Ratio | % |
PXF Growth Ratios
Growth Correlation 3m | 90.7% |
Growth Correlation 12m | 65.1% |
Growth Correlation 5y | 80.8% |
CAGR 5y | 13.57% |
CAGR/Max DD 5y | 0.51 |
Sharpe Ratio 12m | 1.92 |
Alpha | 10.22 |
Beta | 0.706 |
Volatility | 15.01% |
Current Volume | 52.2k |
Average Volume 20d | 53.5k |
As of June 21, 2025, the stock is trading at USD 56.34 with a total of 52,182 shares traded.
Over the past week, the price has changed by -1.02%, over one month by +0.70%, over three months by +5.63% and over the past year by +18.53%.
Yes. Based on ValueRay´s Analyses, Invesco FTSE RAFI Developed (NYSE ARCA:PXF) is currently (June 2025) a good stock to buy. It has a ValueRay Growth Rating of 70.66 and therefor a clear technical positive rating according to historical growth.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of PXF is around 58.10 USD . This means that PXF is currently overvalued and has a potential downside of 3.12%.
Invesco FTSE RAFI Developed has no consensus analysts rating.
According to our own proprietary Forecast Model, PXF Invesco FTSE RAFI Developed will be worth about 64.6 in June 2026. The stock is currently trading at 56.34. This means that the stock has a potential upside of +14.68%.
Issuer | Target | Up/Down from current |
---|---|---|
Wallstreet Target Price | - | - |
Analysts Target Price | - | - |
ValueRay Target Price | 64.6 | 14.7% |